Mylan signs license and supply agreement with Natco
The agreement grants Mylan exclusive distribution rights in the US and all major markets in Europe, Australia, New Zealand, Japan and Canada and includes an option to expand
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
Under the new collaboration agreement WuXi PharmaTech will synthesize compounds, according to AstraZeneca’s designs, which will further expand AstraZeneca’s global compound collection. In April 2006, WuXi PharmaTech and